Denali Therapeutics (NASDAQ:DNLI) Issues Earnings Results

Denali Therapeutics (NASDAQ:DNLI) released its quarterly earnings data on Tuesday. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.64, FiscalAI reports. The firm had revenue of $17.78 million during the quarter, compared to analysts’ expectations of $12.67 million. During the same quarter in the previous year, the firm posted ($0.74) EPS.

Here are the key takeaways from Denali Therapeutics’ conference call:

• AVLAYAH net product revenue reached $17.8 million in Q3, nearly five times the first full-quarter result and above the company’s $10 million–$12 million guidance. Denali expects Q4 revenue of $30 million–$32 million, supported by expanding payer coverage, patient starts, and a new permanent J-code.
• AVLAYAH commercial access expanded to more than 70% of covered commercial lives, while 20 state Medicaid programs now list the treatment. Denali said physician engagement and patient persistence are strong and expects the therapy to become the leading U.S. Hunter syndrome treatment.
• Denali reported progress across its pipeline, including completion of the primary treatment period in the Sanfilippo syndrome type A study and plans for a potential accelerated-approval BLA filing for zafinofusp alfa in 2027. Initial data from Alzheimer’s programs DNL628 and DNL921 are also expected in 2027.
• The company cautioned that the sharp Q3-to-Q4 revenue increase is not a steady-state run rate because some clinical-trial patients transitioned to commercial therapy earlier than expected. COMPASS is not expected to complete until around the end of 2027, with data anticipated in the first half of 2028.
• Denali ended September with approximately $1.01 billion in cash, cash equivalents, and marketable securities, while operating expenses remained essentially flat year over year. Q3 net income of $70.1 million was primarily driven by the one-time $195 million gross proceeds from selling a priority review voucher.

Denali Therapeutics Stock Up 7.7%

DNLI traded up $1.49 during trading on Wednesday, reaching $20.94. The stock had a trading volume of 1,603,161 shares, compared to its average volume of 1,720,142. The stock’s 50 day moving average is $20.42 and its two-hundred day moving average is $21.24. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $3.35 billion, a price-to-earnings ratio of -7.38 and a beta of 1.08. Denali Therapeutics has a one year low of $13.75 and a one year high of $27.30.

More Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: AVLAYAH generated $17.8 million in net product revenue in its second full commercial quarter. Denali expects fourth-quarter revenue of $30 million to $32 million, signaling continued growth. Denali Q3 2026 financial results
• Positive Sentiment: Quarterly results beat expectations: revenue was $17.78 million versus estimates of $12.67 million, and the reported per-share result also exceeded consensus. The company highlighted AVLAYAH’s recognition as 2026’s “Best Biotechnology Product.” Denali Therapeutics soars on earnings beat
• Positive Sentiment: Wedbush raised its price target from $23 to $24 and reiterated an “outperform” rating. BTIG Research reaffirmed its “buy” rating with a $39 target. These calls suggest analysts see substantial potential upside. Wedbush recommendations BTIG Research recommendations
• Positive Sentiment: Denali said its next potential product, zafinofusp for Sanfilippo syndrome type A, remains on track for a 2027 regulatory filing. It expects data from five TransportVehicle programs in 2027, providing potential future catalysts. Denali Q3 2026 business highlights
• Neutral Sentiment: Cash, cash equivalents and marketable securities totaled $1.0 billion. Reported Q3 net income of $70.1 million included a one-time $194 million gain from selling a Priority Review Voucher, so the headline profit may not reflect recurring operations. Denali Q3 2026 financial results

Analyst Upgrades and Downgrades

DNLI has been the subject of several research analyst reports. Robert W. Baird set a $34.00 price objective on Denali Therapeutics in a report on Friday, August 7th. Morgan Stanley boosted their target price on Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. BTIG Research restated a “buy” rating and set a $39.00 target price on shares of Denali Therapeutics in a report on Wednesday. Deutsche Bank Aktiengesellschaft raised their price target on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Finally, Wall Street Zen upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $35.69.

Insider Activity at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,768 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total value of $64,881.92. Following the completion of the transaction, the insider directly owned 278,995 shares in the company, valued at $6,539,642.80. This trade represents a 0.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.70% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.